BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Alvarez-Jimenez M, Priede A, Hetrick SE, Bendall S, Killackey E, Parker AG, McGorry PD, Gleeson JF. Risk factors for relapse following treatment for first episode psychosis: a systematic review and meta-analysis of longitudinal studies. Schizophr Res. 2012;139:116-128. [PMID: 22658527 DOI: 10.1016/j.schres.2012.05.007] [Cited by in Crossref: 223] [Cited by in F6Publishing: 232] [Article Influence: 22.3] [Reference Citation Analysis]
Number Citing Articles
1 Cuesta MJ, Ballesteros A, Sánchez-Torres AM, Amoretti S, López-Ilundain JM, Merchán-Naranjo J, González-Ortega I, Salgado P, Rodriguez-Jimenez R, Roldán-Bejarano A, Sarró S, Ibáñez Á, Usall J, Escartí MJ, Moreno-Izco L, Mezquida G, Parellada M, González-Pinto A, Berrocoso E, Bernardo M; 2EPs group. Relapse of first-episode schizophrenia patients and neurocognitive impairment: The role of dopaminergic and anticholinergic burden. Schizophr Res 2022;248:331-40. [PMID: 36155307 DOI: 10.1016/j.schres.2022.09.014] [Reference Citation Analysis]
2 da Silva AHS, Peixoto LE, dos Santos Martin I, Galera SAF, Vedana KGG, de Freitas LA, Zanetti ACG. Psychotic relapses from the perspective of patients and family members. Archives of Psychiatric Nursing 2022. [DOI: 10.1016/j.apnu.2022.09.012] [Reference Citation Analysis]
3 Dimitrakopoulos S, Stefanatou P, Vlachos I, Selakovic M, Xenaki LA, Ralli I, Soldatos RF, Nianiakas N, Kosteletos I, Foteli S, Mantonakis L, Kollias CT, Stefanis NC. Don't blame psychosis, blame the lack of services: a message for early intervention from the Greek standard care model. BMC Psychiatry 2022;22:565. [PMID: 35996121 DOI: 10.1186/s12888-022-04212-7] [Reference Citation Analysis]
4 Cai H, Zeng C, Zhang X, Liu Y, Wu R, Guo W, Wang J, Wu H, Tang H, Ge X, Yu Y, Zhang S, Cao T, Li N, Liang X, Yang P, Zhang B. Diminished treatment response in relapsed versus first-episode schizophrenia as revealed by a panel of blood-based biomarkers: A combined cross-sectional and longitudinal study. Psychiatry Res 2022;316:114762. [PMID: 35940088 DOI: 10.1016/j.psychres.2022.114762] [Reference Citation Analysis]
5 Veyej N, Moosa MYH. Prescribing patterns of long-acting injectable antipsychotics in a community setting in South Africa. S Afr J Psychiatr 2022;28:1809. [PMID: 35812829 DOI: 10.4102/sajpsychiatry.v28i0.1809] [Reference Citation Analysis]
6 Fraguas D, Almenta Gallego D, Arques-egea S, Gómez-revuelta M, Sánchez-lafuente CG, Hernández Huerta D, Núñez Arias D, Oda Plasencia-garcía B, Parro Torres C, Romero-guillena SL, Ros Cucurul E, Alamo C. Aripiprazole for the treatment of schizophrenia: Recommendations of a panel of Spanish experts on its use in clinical practice. International Journal of Psychiatry in Clinical Practice. [DOI: 10.1080/13651501.2022.2064308] [Reference Citation Analysis]
7 Cochran JM, Fang H, Le Gallo C, Peters-strickland T, Lindenmayer J, Reuteman-fowler JC. Participant Engagement and Symptom Improvement: Aripiprazole Tablets with Sensor for the Treatment of Schizophrenia. PPA 2022;Volume 16:1805-17. [DOI: 10.2147/ppa.s362889] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Lal S, Czesak A, Tibbo P, Joober R, Williams R, Chandrasena R, Otter N, Malla A. Young Adults' Perspectives on Factors Related to Relapse After First-Episode Psychosis: Qualitative Focus Group Study. Psychiatr Serv 2022;:appips202000641. [PMID: 35770426 DOI: 10.1176/appi.ps.202000641] [Reference Citation Analysis]
9 de Haan L, Linszen D, Wouters L, Zwinderman K, Dingemans P. Sustained specialized and family treatment in first-episode schizophrenia or related disorders: a 5-year randomized controlled trial. Psychol Med . [DOI: 10.1017/s003329172200099x] [Reference Citation Analysis]
10 Dellazizzo L, Potvin S, Giguère S, Dumais A. The Potential Paradoxical Neurocognitive Effects of Cannabis Use in Patients with Psychotic Disorders: A Critical Meta-Review of Meta-Analytical Evidence. Cannabis Cannabinoid Res 2022. [PMID: 35666226 DOI: 10.1089/can.2021.0163] [Reference Citation Analysis]
11 Gumley AI, Bradstreet S, Ainsworth J, Allan S, Alvarez-Jimenez M, Birchwood M, Briggs A, Bucci S, Cotton S, Engel L, French P, Lederman R, Lewis S, Machin M, MacLennan G, McLeod H, McMeekin N, Mihalopoulos C, Morton E, Norrie J, Reilly F, Schwannauer M, Singh SP, Sundram S, Thompson A, Williams C, Yung A, Aucott L, Farhall J, Gleeson J. Digital smartphone intervention to recognise and manage early warning signs in schizophrenia to prevent relapse: the EMPOWER feasibility cluster RCT. Health Technol Assess 2022;26:1-174. [PMID: 35639493 DOI: 10.3310/HLZE0479] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Gumley AI, Bradstreet S, Ainsworth J, Allan S, Alvarez-jimenez M, Aucott L, Birchwood M, Briggs A, Bucci S, Cotton SM, Engel L, French P, Lederman R, Lewis S, Machin M, Maclennan G, Mcleod H, Mcmeekin N, Mihalopoulos C, Morton E, Norrie J, Schwannauer M, Singh SP, Sundram S, Thompson A, Williams C, Yung AR, Farhall J, Gleeson J. The EMPOWER blended digital intervention for relapse prevention in schizophrenia: a feasibility cluster randomised controlled trial in Scotland and Australia. The Lancet Psychiatry 2022;9:477-86. [DOI: 10.1016/s2215-0366(22)00103-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Facal F, Arrojo M, Paz E, Páramo M, Costas J. Association between psychiatric hospitalizations of patients with schizophrenia and polygenic risk scores based on genes with altered expression by antipsychotics. Acta Psychiatr Scand 2022. [PMID: 35582973 DOI: 10.1111/acps.13444] [Reference Citation Analysis]
14 Bioque M, Mezquida G, Amoretti S, García-rizo C, López-ilundain JM, Diaz-caneja CM, Zorrilla I, Mané A, Rodriguez-jimenez R, Corripio I, Pomarol-clotet E, Ibáñez Á, Usall J, Contreras F, Mas S, Vázquez-bourgon J, Cuesta MJ, Parellada M, González-pinto A, Hidalgo-figueroa M, Bernardo M. Clinical and treatment predictors of relapse during a three-year follow-up of a cohort of first episodes of schizophrenia. Schizophrenia Research 2022;243:32-42. [DOI: 10.1016/j.schres.2022.02.026] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
15 Lee DY, Kim C, Lee S, Son SJ, Cho SM, Cho YH, Lim J, Park RW. Psychosis Relapse Prediction Leveraging Electronic Health Records Data and Natural Language Processing Enrichment Methods. Front Psychiatry 2022;13:844442. [PMID: 35479497 DOI: 10.3389/fpsyt.2022.844442] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
16 Farcas A, Iftene F. Findings, limitations and new directions in tACS studies in schizophrenia research: A scoping review. J Psychiatr Res 2022;151:291-8. [PMID: 35525231 DOI: 10.1016/j.jpsychires.2022.04.036] [Reference Citation Analysis]
17 Erickson SK, Vorwerk ML. A perspective review of cannabis use and sexual offenses. Behav Sci Law 2022. [PMID: 35445434 DOI: 10.1002/bsl.2571] [Reference Citation Analysis]
18 Yen K, Liu CC, Lin YT, Chien YL, Hsieh MH, Liu CM, Hwang TJ, Liao WH, Hwu HG. Discontinuing Antipsychotic Medication After Remission from First-Episode Psychosis: A Survey of Psychiatrists' Attitudes in Taiwan. Neuropsychiatr Dis Treat 2022;18:465-75. [PMID: 35261544 DOI: 10.2147/NDT.S339866] [Reference Citation Analysis]
19 Kline ER, Ferrara M, Li F, D'souza DC, Keshavan M, Srihari VH. Timing of cannabis exposure relative to prodrome and psychosis onset in a community-based first episode psychosis sample. Journal of Psychiatric Research 2022;147:248-53. [DOI: 10.1016/j.jpsychires.2022.01.039] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
20 Kim SK, Lee M, Jeong H, Jang YM. Effectiveness of mobile applications for patients with severe mental illness: A meta-analysis of randomized controlled trials. Jpn J Nurs Sci 2022;:e12476. [PMID: 35174976 DOI: 10.1111/jjns.12476] [Reference Citation Analysis]
21 Amoretti S, Verdolini N, Varo C, Mezquida G, Sánchez-Torres AM, Vieta E, Garcia-Rizo C, Lobo A, González-Pinto A, Abregú-Crespo R, Corripio I, Serra M, Serna E, Mané A, Ramos-Quiroga JA, Ribases M, Cuesta MJ, Bernardo M; PEPs Group. Is the effect of cognitive reserve in longitudinal outcomes in first-episode psychoses dependent on the use of cannabis? J Affect Disord 2022:S0165-0327(22)00086-6. [PMID: 35066012 DOI: 10.1016/j.jad.2022.01.077] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
22 Malla A, Iyer SN, Joober R, Rangaswamy T, Ramachandran P, Schmitz N, Taksal A, Mohan G, Margolese HC. An observational study of antipsychotic medication discontinuation in first-episode psychosis: clinical and functional outcomes. Soc Psychiatry Psychiatr Epidemiol 2022. [PMID: 35041015 DOI: 10.1007/s00127-022-02230-0] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
23 Johansen KK, Hounsgaard L, Hansen JP, Fluttert FAJ. Early Recognition Method - Amplifying relapse management in community mental health care; a comprehensive study of the effects on relapse and readmission. Arch Psychiatr Nurs 2021;35:587-94. [PMID: 34861950 DOI: 10.1016/j.apnu.2021.08.004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
24 Gallinat C, Moessner M, Apondo S, Thomann PA, Herpertz SC, Bauer S. Feasibility of an Intervention Delivered via Mobile Phone and Internet to Improve the Continuity of Care in Schizophrenia: A Randomized Controlled Pilot Study. Int J Environ Res Public Health 2021;18:12391. [PMID: 34886117 DOI: 10.3390/ijerph182312391] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
25 Agid O, Remington G, Fung C, Nightingale NM, Duclos M, Anger GJ. Real-World Utilization Patterns of Long-Acting Injectable Antipsychotics in Canada: A Retrospective Study : Modèles concrets d'utilisation d'antipsychotiques injectables à action prolongée au Canada : une étude rétrospective. Can J Psychiatry 2021;:7067437211055413. [PMID: 34792401 DOI: 10.1177/07067437211055413] [Reference Citation Analysis]
26 Catalan A, Richter A, Salazar de Pablo G, Vaquerizo-Serrano J, Mancebo G, Pedruzo B, Aymerich C, Solmi M, González-Torres MÁ, Gil P, McGuire P, Fusar-Poli P. Proportion and predictors of remission and recovery in first-episode psychosis: Systematic review and meta-analysis. Eur Psychiatry 2021;64:e69. [PMID: 34730080 DOI: 10.1192/j.eurpsy.2021.2246] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
27 Gündoğmuş İ, Aydin MB, Öz S, Taşçi AB, Uzun Ö. Clinical and demographic factors associated with early relapse in patients with schizophrenia: a naturalistic observation study. Int Clin Psychopharmacol 2021;36:288-95. [PMID: 34417787 DOI: 10.1097/YIC.0000000000000377] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
28 Devrımcı Özgüven H, Kir Y. Long Acting Injectable Antipsychotics in the Treatment of Schizophrenia and Bipolar Disorder. Noro Psikiyatr Ars 2021;58:S47-52. [PMID: 34658635 DOI: 10.29399/npa.27480] [Reference Citation Analysis]
29 Brasso C, Cisotto M, Ghirardini C, Pennazio F, Villari V, Rocca P. Accuracy of self-reported adherence and therapeutic drug monitoring in a psychiatric emergency ward. Psychiatry Res 2021;305:114214. [PMID: 34587569 DOI: 10.1016/j.psychres.2021.114214] [Reference Citation Analysis]
30 Caqueo-Urízar A, Urzúa A, Mena-Chamorro P, Bravo de la Fuente J. Effects of Adherence to Pharmacological Treatment on the Recovery of Patients with Schizophrenia. Healthcare (Basel) 2021;9:1230. [PMID: 34575005 DOI: 10.3390/healthcare9091230] [Reference Citation Analysis]
31 Haesebaert F, El Oussoul S, Pavard A, Fabre D, Cellard C, Magaud L, Subtil F, Damiolini E, Fakra E, Haesebaert J. PLAN-e-PSY, a mobile application to improve case management and patient's functioning in first episode psychosis: protocol for an open-label, multicentre, superiority, randomised controlled trial. BMJ Open 2021;11:e050433. [PMID: 34521670 DOI: 10.1136/bmjopen-2021-050433] [Reference Citation Analysis]
32 Bernardo M, Amoretti S, Cuesta MJ, Parellada M, Mezquida G, González-Pinto A, Bergé D, Lobo A, Aguilar EJ, Usall J, Corripio I, Bobes J, Rodríguez-Jiménez R, Sarró S, Contreras F, Ibáñez Á, Gutiérrez M, Micó JA; 2EPs Group., acronym 2EPs Group responds to the authorship of the principal investigators of the fifteen centres that have participated in this coordinated multicenter project. The prevention of relapses in first episodes of schizophrenia: The 2EPs Project, background, rationale and study design. Rev Psiquiatr Salud Ment (Engl Ed) 2021;14:164-76. [PMID: 34456031 DOI: 10.1016/j.rpsmen.2021.08.001] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
33 Montes JM, Hernández-Huerta D. Impact of the COVID-19 pandemic on acute inpatient psychiatric units in Spain. Psychiatry Res 2021;304:114136. [PMID: 34332433 DOI: 10.1016/j.psychres.2021.114136] [Reference Citation Analysis]
34 Prakash J, Chatterjee K, Srivastava K, Chauhan VS. First-episode psychosis: How long does it last? A review of evolution and trajectory. Ind Psychiatry J 2021;30:198-206. [PMID: 35017801 DOI: 10.4103/ipj.ipj_38_21] [Reference Citation Analysis]
35 Athanassiou M, Dumais A, Gnanhoue G, Abdel-Baki A, Jutras-Aswad D, Potvin S. A systematic review of longitudinal studies investigating the impact of cannabis use in patients with psychotic disorders. Expert Rev Neurother 2021;21:779-91. [PMID: 34120548 DOI: 10.1080/14737175.2021.1942845] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
36 Rubio JM, Taipale H, Tanskanen A, Correll CU, Kane JM, Tiihonen J. Long-term Continuity of Antipsychotic Treatment for Schizophrenia: A Nationwide Study. Schizophr Bull 2021:sbab063. [PMID: 34129663 DOI: 10.1093/schbul/sbab063] [Cited by in Crossref: 1] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
37 Ji Y, Liu B, Song J, Pan R, Cheng J, Su H, Wang H. Particulate matter pollution associated with schizophrenia hospital re-admissions: a time-series study in a coastal Chinese city. Environ Sci Pollut Res Int 2021. [PMID: 34115296 DOI: 10.1007/s11356-021-14816-3] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
38 Liu CC, Takeuchi H. Achieving the Lowest Effective Antipsychotic Dose for Patients with Remitted Psychosis: A Proposed Guided Dose-Reduction Algorithm. CNS Drugs 2020;34:117-26. [PMID: 31741178 DOI: 10.1007/s40263-019-00682-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
39 Arnold C, Farhall J, Villagonzalo KA, Sharma K, Thomas N. Engagement with online psychosocial interventions for psychosis: A review and synthesis of relevant factors. Internet Interv 2021;25:100411. [PMID: 34401370 DOI: 10.1016/j.invent.2021.100411] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
40 Alvarez-Jimenez M, Koval P, Schmaal L, Bendall S, O'Sullivan S, Cagliarini D, D'Alfonso S, Rice S, Valentine L, Penn DL, Miles C, Russon P, Phillips J, McEnery C, Lederman R, Killackey E, Mihalopoulos C, Gonzalez-Blanch C, Gilbertson T, Lal S, Cotton SM, Herrman H, McGorry PD, Gleeson JFM. The Horyzons project: a randomized controlled trial of a novel online social therapy to maintain treatment effects from specialist first-episode psychosis services. World Psychiatry 2021;20:233-43. [PMID: 34002511 DOI: 10.1002/wps.20858] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 20.0] [Reference Citation Analysis]
41 Sired R, Griffith E, Jamalamadaka T, Salkovskis P. Negative interpretations of ambiguous 'psychosis-like' and 'anxiety-like' experiences in recovery from psychosis or anxiety. Br J Clin Psychol 2021. [PMID: 33982800 DOI: 10.1111/bjc.12299] [Reference Citation Analysis]
42 Moges S, Belete T, Mekonen T, Menberu M. Lifetime relapse and its associated factors among people with schizophrenia spectrum disorders who are on follow up at Comprehensive Specialized Hospitals in Amhara region, Ethiopia: a cross-sectional study. Int J Ment Health Syst 2021;15:42. [PMID: 33957944 DOI: 10.1186/s13033-021-00464-0] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
43 Wang Q, Zhu X, Jiang X, Li M, Chang R, Chen B, Liu J. Relationship between stressful life events, coping styles, and schizophrenia relapse. Int J Ment Health Nurs 2021;30:1149-59. [PMID: 33960095 DOI: 10.1111/inm.12865] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
44 Segarra R, Recio-Barbero M, Sáenz-Herrero M, Mentxaka O, Cabezas-Garduño J, Eguíluz JI, Callado LF. Oral and Palmitate Paliperidone Long-Acting Injectable Formulations use in Schizophrenia Spectrum Disorders: a retrospective cohort study from the CRUPEP First Episode Psychosis Intervention Program. Int J Neuropsychopharmacol 2021:pyab021. [PMID: 34009370 DOI: 10.1093/ijnp/pyab021] [Reference Citation Analysis]
45 Olivares JM, González-Pinto A, Páramo M; PROSIGO Study Group. Predictors of persistence in patients with schizophrenia treated with aripiprazole once-monthly long-acting injection in the Spanish clinical practice: a retrospective, observational study. Eur Psychiatry 2021;64:e40. [PMID: 33840396 DOI: 10.1192/j.eurpsy.2021.23] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
46 Kitamura A, Takagaki T, Nemoto D, Tomita Y, Nishibe H, Kakuyama H. Pharmacokinetic Evaluation of Blonanserin Transdermal Patch: Population Analysis and Simulation of Plasma Concentration and Dopamine D2 Receptor Occupancy in Clinical Settings. J Clin Pharmacol 2021;61:1069-80. [PMID: 33599975 DOI: 10.1002/jcph.1835] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
47 O'sullivan S, Schmaal L, D'alfonso S, Toenders YJ, Valentine L, Mcenery C, Bendall S, Nelson B, Gleeson J, Alvarez-jimenez M. Characterising Usage of a Multicomponent Digital Intervention to Predict Treatment Outcomes in First-Episode Psychosis: A Cluster Analysis (Preprint). JMIR Mental Health. [DOI: 10.2196/29211] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
48 Liu CC, Hsieh MH, Chien YL, Liu CM, Lin YT, Hwang TJ, Hwu HG. Protocol of guided antipsychotic reduction to reach minimum effective dose (GARMED) in patients with remitted psychosis based on pragmatic design. Early Interv Psychiatry 2021. [PMID: 33751764 DOI: 10.1111/eip.13144] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
49 Katsampa D, Akther SF, Hollander AC, Dal H, Dalman C, Kirkbride JB. Inequalities in Psychiatric Service Use and Mortality by Migrant Status Following a First Diagnosis of Psychotic Disorder: A Swedish Cohort Study of 1.3M People. Schizophr Bull Open 2021;2:sgab009. [PMID: 33898991 DOI: 10.1093/schizbullopen/sgab009] [Reference Citation Analysis]
50 Benelmokhtar JM, Chiliza B, Phahladira L, Emsley R, Asmal L. Factors associated with dropout at 2 years post-initiation of treatment in the first episode of schizophrenia. S Afr J Psychiatr 2021;27:1657. [PMID: 33824760 DOI: 10.4102/sajpsychiatry.v27i0.1657] [Reference Citation Analysis]
51 Patel C, Emond B, Morrison L, Lafeuille MH, Lefebvre P, Lin D, Kim E, Joshi K. Risk of subsequent relapses and corresponding healthcare costs among recently-relapsed Medicaid patients with schizophrenia: a real-world retrospective cohort study. Curr Med Res Opin 2021;37:665-74. [PMID: 33507831 DOI: 10.1080/03007995.2021.1882977] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
52 Ma CF, Chan SKW, Chung YL, Ng SM, Hui CLM, Suen YN, Chen EYH. The predictive power of expressed emotion and its components in relapse of schizophrenia: a meta-analysis and meta-regression. Psychol Med 2021;51:365-75. [PMID: 33568244 DOI: 10.1017/S0033291721000209] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
53 Camacho-Gomez M, Castellvi P. Effectiveness of Family Intervention for Preventing Relapse in First-Episode Psychosis Until 24 Months of Follow-up: A Systematic Review With Meta-analysis of Randomized Controlled Trials. Schizophr Bull 2020;46:98-109. [PMID: 31050757 DOI: 10.1093/schbul/sbz038] [Cited by in Crossref: 11] [Cited by in F6Publishing: 16] [Article Influence: 11.0] [Reference Citation Analysis]
54 da Silva AHS, de Freitas LA, Shuhama R, Del-Ben CM, Vedana KGG, Martin IDS, Zanetti ACG. Family environment and depressive episode are associated with relapse after first-episode psychosis. J Psychiatr Ment Health Nurs 2021. [PMID: 33544947 DOI: 10.1111/jpm.12735] [Reference Citation Analysis]
55 Kidd S, McKenzie K, Wang W, Agrawal S, Voineskos A. Examining a Digital Health Approach for Advancing Schizophrenia Illness Self-Management and Provider Engagement: Protocol for a Feasibility Trial. JMIR Res Protoc 2021;10:e24736. [PMID: 33492235 DOI: 10.2196/24736] [Reference Citation Analysis]
56 He X, Sun T, Wang L, Jiang X. Pipette-tip micro-solid phase extraction based on melamine-foam@polydopamine followed by ultra-high-performance liquid chromatography-quadrupole-time-of-flight mass spectrometry for detection of psychotropic drugs in human serum. J Chromatogr B Analyt Technol Biomed Life Sci 2021;1163:122499. [PMID: 33388524 DOI: 10.1016/j.jchromb.2020.122499] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
57 Howes OD, Whitehurst T, Shatalina E, Townsend L, Onwordi EC, Mak TLA, Arumuham A, O'Brien O, Lobo M, Vano L, Zahid U, Butler E, Osugo M. The clinical significance of duration of untreated psychosis: an umbrella review and random-effects meta-analysis. World Psychiatry 2021;20:75-95. [PMID: 33432766 DOI: 10.1002/wps.20822] [Cited by in Crossref: 34] [Cited by in F6Publishing: 34] [Article Influence: 34.0] [Reference Citation Analysis]
58 Rubio JM, Malhotra AK, Kane JM. Towards a framework to develop neuroimaging biomarkers of relapse in schizophrenia. Behav Brain Res 2021;402:113099. [PMID: 33417996 DOI: 10.1016/j.bbr.2020.113099] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
59 Wisner KM, Chiappelli J, Savransky A, Fisseha F, Rowland LM, Kochunov P, Hong LE. Cingulum and abnormal psychological stress response in schizophrenia. Brain Imaging Behav 2020;14:548-61. [PMID: 31123971 DOI: 10.1007/s11682-019-00120-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
60 Ouellet-plamondon C, Abdel-baki A, Jutras-aswad D. Premier épisode psychotique et trouble de l’usage de substance concomitants : revue narrative des meilleures pratiques et pistes d’approches adaptées pour l’évaluation et le suivi. Santé mentale au Québec 2021;46:277. [DOI: 10.7202/1088186ar] [Reference Citation Analysis]
61 Gao J, Wei Q, Pan R, Yi W, Xu Z, Duan J, Tang C, He Y, Liu X, Song S, Su H. Elevated environmental PM2.5 increases risk of schizophrenia relapse: Mediation of inflammatory cytokines. Science of The Total Environment 2021;753:142008. [DOI: 10.1016/j.scitotenv.2020.142008] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
62 Pothier W, Lecomte T, Cellard C, Delfosse C, Fortier S, Corbière M. La réinsertion professionnelle et le retour aux études chez les personnes en début d’évolution d’un trouble psychotique. Santé mentale au Québec 2021;46:161. [DOI: 10.7202/1088182ar] [Reference Citation Analysis]
63 Bertulies-esposito B, Sicotte R, Iyer SN, Delfosse C, Girard N, Nolin M, Villeneuve M, Conus P, Abdel-baki A. Détection et intervention précoce pour la psychose : pourquoi et comment ? Santé mentale au Québec 2021;46:45. [DOI: 10.7202/1088178ar] [Reference Citation Analysis]
64 Zhu X, Song H, Chang R, Chen B, Song Y, Liu J, Wang K. Combining compensatory cognitive training and medication self-management skills training, in inpatients with schizophrenia: A three-arm parallel, single-blind, randomized controlled trial. Gen Hosp Psychiatry 2021;69:94-103. [PMID: 33588196 DOI: 10.1016/j.genhosppsych.2020.12.012] [Reference Citation Analysis]
65 Hasin D, Walsh C. Cannabis Use, Cannabis Use Disorder, and Comorbid Psychiatric Illness: A Narrative Review. J Clin Med 2020;10:E15. [PMID: 33374666 DOI: 10.3390/jcm10010015] [Cited by in Crossref: 2] [Cited by in F6Publishing: 15] [Article Influence: 1.0] [Reference Citation Analysis]
66 Guitter M, Laprevote V, Lala A, Sturzu L, Dobre D, Schwan R. Rate and predictors of interrupted patient follow-up after first-episode psychosis - a retrospective cohort study in France. Early Interv Psychiatry 2020. [PMID: 33350169 DOI: 10.1111/eip.13093] [Reference Citation Analysis]
67 Berendsen S, van Tricht MJ, Tedja A, Burger TJ, de Koning MB, de Haan L. The bumpy road to achieve reliability of clinical profile characteristics in psychosis and related disorders. Int J Methods Psychiatr Res 2021;30:e1858. [PMID: 33615618 DOI: 10.1002/mpr.1858] [Reference Citation Analysis]
68 Murillo-García N, Setién-Suero E, Pardo-de-Santayana G, Murillo-García M, Pelayo-Terán JM, Crespo-Facorro B, Ayesa-Arriola R. Entire duration of active psychosis and neurocognitive performance in first-episode non-affective psychosis. Early Interv Psychiatry 2021;15:1266-75. [PMID: 33244853 DOI: 10.1111/eip.13077] [Reference Citation Analysis]
69 Bucci S, Berry K, Barrowclough C, Haddock G. Family Interventions in Psychosis: A Review of the Evidence and Barriers to Implementation. Australian Psychologist 2016;51:62-8. [DOI: 10.1111/ap.12172] [Cited by in Crossref: 31] [Cited by in F6Publishing: 26] [Article Influence: 15.5] [Reference Citation Analysis]
70 Palaniyappan L, Sukumar N. Reconsidering brain tissue changes as a mechanistic focus for early intervention in psychiatry. J Psychiatry Neurosci 2020;44:373-8. [PMID: 33119489 [PMID: 33119489 DOI: 10.1503/jpn.200172] [Cited by in Crossref: 4] [Article Influence: 2.0] [Reference Citation Analysis]
71 Martland N, Martland R, Cullen AE, Bhattacharyya S. Are adult stressful life events associated with psychotic relapse? A systematic review of 23 studies. Psychol Med 2020;50:2302-16. [PMID: 33054892 DOI: 10.1017/S0033291720003554] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 6.0] [Reference Citation Analysis]
72 Bhattacharyya S, Schoeler T, Patel R, di Forti M, Murray RM, McGuire P. Individualized prediction of 2-year risk of relapse as indexed by psychiatric hospitalization following psychosis onset: Model development in two first episode samples. Schizophr Res 2021;228:483-92. [PMID: 33067054 DOI: 10.1016/j.schres.2020.09.016] [Cited by in Crossref: 1] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
73 Bernardo M, Amoretti S, Cuesta MJ, Parellada M, Mezquida G, González-Pinto A, Bergé D, Lobo A, Aguilar EJ, Usall J, Corripio I, Bobes J, Rodríguez-Jiménez R, Sarró S, Contreras F, Ibáñez Á, Gutiérrez M, Micó JA; 2EPs Group., acronym 2EPs Group responds to the authorship of the principal investigators of the fifteen centres that have participated in this coordinated multicenter project. The prevention of relapses in first episodes of schizophrenia: The 2EPs Project, background, rationale and study design. Rev Psiquiatr Salud Ment 2021;14:164-76. [PMID: 33020032 DOI: 10.1016/j.rpsm.2020.07.004] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
74 Henson P, Wisniewski H, Stromeyer Iv C, Torous J. Digital Health Around Clinical High Risk and First-Episode Psychosis. Curr Psychiatry Rep 2020;22:58. [PMID: 32880764 DOI: 10.1007/s11920-020-01184-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
75 Rubio JM, Schoretsanitis G, John M, Tiihonen J, Taipale H, Guinart D, Malhotra AK, Correll CU, Kane JM. Psychosis relapse during treatment with long-acting injectable antipsychotics in individuals with schizophrenia-spectrum disorders: an individual participant data meta-analysis. The Lancet Psychiatry 2020;7:749-61. [DOI: 10.1016/s2215-0366(20)30264-9] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 11.5] [Reference Citation Analysis]
76 Birnbaum ML, Kulkarni PP, Van Meter A, Chen V, Rizvi AF, Arenare E, De Choudhury M, Kane JM. Utilizing Machine Learning on Internet Search Activity to Support the Diagnostic Process and Relapse Detection in Young Individuals With Early Psychosis: Feasibility Study. JMIR Ment Health 2020;7:e19348. [PMID: 32870161 DOI: 10.2196/19348] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
77 Steare T, O'Hanlon P, Eskinazi M, Osborn D, Lloyd-Evans B, Jones R, Rostill H, Amani S, Johnson S. Smartphone-delivered self-management for first-episode psychosis: the ARIES feasibility randomised controlled trial. BMJ Open 2020;10:e034927. [PMID: 32847902 DOI: 10.1136/bmjopen-2019-034927] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
78 Shannon A, McGuire D, Brown E, O'Donoghue B. A systematic review of the effectiveness of group-based exercise interventions for individuals with first episode psychosis. Psychiatry Res 2020;293:113402. [PMID: 32862064 DOI: 10.1016/j.psychres.2020.113402] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
79 Kottaram A, Johnston LA, Tian Y, Ganella EP, Laskaris L, Cocchi L, McGorry P, Pantelis C, Kotagiri R, Cropley V, Zalesky A. Predicting individual improvement in schizophrenia symptom severity at 1-year follow-up: Comparison of connectomic, structural, and clinical predictors. Hum Brain Mapp 2020;41:3342-57. [PMID: 32469448 DOI: 10.1002/hbm.25020] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
80 Alvarez-Jimenez M, Rice S, D'Alfonso S, Leicester S, Bendall S, Pryor I, Russon P, McEnery C, Santesteban-Echarri O, Da Costa G, Gilbertson T, Valentine L, Solves L, Ratheesh A, McGorry PD, Gleeson J. A Novel Multimodal Digital Service (Moderated Online Social Therapy+) for Help-Seeking Young People Experiencing Mental Ill-Health: Pilot Evaluation Within a National Youth E-Mental Health Service. J Med Internet Res 2020;22:e17155. [PMID: 32788151 DOI: 10.2196/17155] [Cited by in Crossref: 14] [Cited by in F6Publishing: 22] [Article Influence: 7.0] [Reference Citation Analysis]
81 Gibson CL, Bassir Nia A, Spriggs SA, DeFrancisco D, Swift A, Perkel C, Zhong X, Mazumdar M, Fernandez N, Patel M, Kim-Schulze S, Hurd YL. Cannabinoid use in psychotic patients impacts inflammatory levels and their association with psychosis severity. Psychiatry Res 2020;293:113380. [PMID: 32818918 DOI: 10.1016/j.psychres.2020.113380] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
82 Takeuchi S, So R. Effect of a hospital-based multidisciplinary outreach service on readmission prevention for first-episode schizophrenia: A propensity score-matched cohort study. Asian J Psychiatr 2020;52:102133. [PMID: 32361474 DOI: 10.1016/j.ajp.2020.102133] [Reference Citation Analysis]
83 Valentine L, McEnery C, Bell I, O'Sullivan S, Pryor I, Gleeson J, Bendall S, Alvarez-Jimenez M. Blended Digital and Face-to-Face Care for First-Episode Psychosis Treatment in Young People: Qualitative Study. JMIR Ment Health 2020;7:e18990. [PMID: 32720904 DOI: 10.2196/18990] [Cited by in Crossref: 3] [Cited by in F6Publishing: 11] [Article Influence: 1.5] [Reference Citation Analysis]
84 Ferreira A, Coentre R. A systematic review of tobacco use in first-episode psychosis. The European Journal of Psychiatry 2020;34:132-42. [DOI: 10.1016/j.ejpsy.2020.03.005] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
85 Best MW, Law H, Pyle M, Morrison AP. Relationships between psychiatric symptoms, functioning and personal recovery in psychosis. Schizophr Res 2020;223:112-8. [PMID: 32620428 DOI: 10.1016/j.schres.2020.06.026] [Cited by in Crossref: 5] [Cited by in F6Publishing: 15] [Article Influence: 2.5] [Reference Citation Analysis]
86 da Silva AHS, de Souza Tressoldi L, de Azevedo-Marques JM, Shuhama R, Del-Ben CM, Galera SAF, da Silva Gherardi-Donato EC, Vedana KGG, Zanetti ACG. Predictors of Expressed Emotion in First Episode Psychosis. Issues Ment Health Nurs 2020;41:908-15. [PMID: 32568611 DOI: 10.1080/01612840.2020.1749916] [Reference Citation Analysis]
87 Madero S, Oliveras C, Pons MT, Sague M, López-Pelayo H, Gual A, Balcells M. Cannabis use the week before admission to psychiatric in-patient service as a marker of severity. J Psychiatr Res 2020;129:40-6. [PMID: 32563776 DOI: 10.1016/j.jpsychires.2020.05.028] [Reference Citation Analysis]
88 Roberts T, Gureje O, Thara R, Hutchinson G, Cohen A, Weiss HA, John S, Lee Pow J, Donald C, Olley B, Miguel Esponda G, Murray RM, Morgan C. INTREPID II: protocol for a multistudy programme of research on untreated psychosis in India, Nigeria and Trinidad. BMJ Open 2020;10:e039004. [PMID: 32565481 DOI: 10.1136/bmjopen-2020-039004] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
89 Charles S, Kirkbride JB, Onwumere J, Lyons N, Man LC, Floyd C, Widuch K, Brown L, James G, Afsharzadegan R, Souray J, Raune D. Carer subjective burden after first-episode psychosis: Types and predictors. A multilevel statistical approach. Int J Soc Psychiatry 2021;67:73-83. [PMID: 32522056 DOI: 10.1177/0020764020930041] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
90 Pardo-de-santayana G, Vázquez-bourgon J, Gómez-revuelta M, Ayesa-arriola R, Ortiz-garcia de la Foz V, Crespo-facorro B, Pelayo-terán JM. Duration of active psychosis during early phases of the illness and functional outcome: The PAFIP 10-year follow-up study. Schizophrenia Research 2020;220:240-7. [DOI: 10.1016/j.schres.2020.03.009] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
91 Campbell PD, Granato M. Zebrafish as a tool to study schizophrenia-associated copy number variants. Dis Model Mech 2020;13:dmm043877. [PMID: 32433025 DOI: 10.1242/dmm.043877] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
92 Tatar O, Bastien G, Abdel-Baki A, Huỳnh C, Jutras-Aswad D. A systematic review of technology-based psychotherapeutic interventions for decreasing cannabis use in patients with psychosis. Psychiatry Res 2020;288:112940. [PMID: 32344316 DOI: 10.1016/j.psychres.2020.112940] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
93 Brown E, Bedi G, Mcgorry P, O’donoghue B. Rates and Predictors of Relapse in First-Episode Psychosis: An Australian Cohort Study. Schizophrenia Bulletin Open 2020;1:sgaa017. [DOI: 10.1093/schizbullopen/sgaa017] [Cited by in Crossref: 3] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
94 Ghabrash MF, Coronado-Montoya S, Aoun J, Gagné AA, Mansour F, Ouellet-Plamondon C, Trépanier A, Jutras-Aswad D. Cannabidiol for the treatment of psychosis among patients with schizophrenia and other primary psychotic disorders: A systematic review with a risk of bias assessment. Psychiatry Res 2020;286:112890. [PMID: 32126328 DOI: 10.1016/j.psychres.2020.112890] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 7.5] [Reference Citation Analysis]
95 Wu CS, Luedtke AR, Sadikova E, Tsai HJ, Liao SC, Liu CC, Gau SS, VanderWeele TJ, Kessler RC. Development and Validation of a Machine Learning Individualized Treatment Rule in First-Episode Schizophrenia. JAMA Netw Open 2020;3:e1921660. [PMID: 32083693 DOI: 10.1001/jamanetworkopen.2019.21660] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
96 Usuki M, Kamiura Y, Okubo R, Yamanouchi Y. National database study on the use of long-acting antipsychotic injections and hospital readmission proportions in patients with schizophrenia in Japan. Psychiatry Clin Neurosci 2020;74:211-7. [PMID: 31875333 DOI: 10.1111/pcn.12970] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
97 Gumley A, Bradstreet S, Ainsworth J, Allan S, Alvarez-Jimenez M, Beattie L, Bell I, Birchwood M, Briggs A, Bucci S, Castagnini E, Clark A, Cotton SM, Engel L, French P, Lederman R, Lewis S, Machin M, MacLennan G, Matrunola C, McLeod H, McMeekin N, Mihalopoulos C, Morton E, Norrie J, Reilly F, Schwannauer M, Singh SP, Smith L, Sundram S, Thomson D, Thompson A, Whitehill H, Wilson-Kay A, Williams C, Yung A, Farhall J, Gleeson J. Early Signs Monitoring to Prevent Relapse in Psychosis and Promote Well-Being, Engagement, and Recovery: Protocol for a Feasibility Cluster Randomized Controlled Trial Harnessing Mobile Phone Technology Blended With Peer Support. JMIR Res Protoc 2020;9:e15058. [PMID: 31917372 DOI: 10.2196/15058] [Cited by in Crossref: 9] [Cited by in F6Publishing: 14] [Article Influence: 4.5] [Reference Citation Analysis]
98 Giordano G, Tomassini L, Cuomo I, Amici E, Perrini F, Callovini G, Carannante A, Kotzalidis GD, De Filippis S. Aripiprazole Long-Acting Injection During First Episode Schizophrenia-An Exploratory Analysis. Front Psychiatry 2019;10:935. [PMID: 31969843 DOI: 10.3389/fpsyt.2019.00935] [Cited by in Crossref: 2] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
99 Wright A, Cather C, Gilman J, Evins AE. The Changing Legal Landscape of Cannabis Use and Its Role in Youth-onset Psychosis. Child and Adolescent Psychiatric Clinics of North America 2020;29:145-56. [DOI: 10.1016/j.chc.2019.08.016] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 3.5] [Reference Citation Analysis]
100 Barnes TR, Drake R, Paton C, Cooper SJ, Deakin B, Ferrier IN, Gregory CJ, Haddad PM, Howes OD, Jones I, Joyce EM, Lewis S, Lingford-hughes A, Maccabe JH, Owens DC, Patel MX, Sinclair JM, Stone JM, Talbot PS, Upthegrove R, Wieck A, Yung AR. Evidence-based guidelines for the pharmacological treatment of schizophrenia: Updated recommendations from the British Association for Psychopharmacology. J Psychopharmacol 2020;34:3-78. [DOI: 10.1177/0269881119889296] [Cited by in Crossref: 47] [Cited by in F6Publishing: 73] [Article Influence: 15.7] [Reference Citation Analysis]
101 Allan S, Bradstreet S, McLeod HJ, Gleeson J, Farhall J, Lambrou M, Clark A, Gumley AI. Perspectives of patients, carers and mental health staff on early warning signs of relapse in psychosis: a qualitative investigation. BJPsych Open 2019;6:e3. [PMID: 31826793 DOI: 10.1192/bjo.2019.88] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
102 Waggershauser M, Steinert T. Breakthrough psychosis under antipsychotic maintenance treatment and social stress. Psychol Med 2019;49:2808-9. [PMID: 31462341 DOI: 10.1017/S003329171900206X] [Reference Citation Analysis]
103 Emsley R, Asmal L, Rubio JM, Correll CU, Kane JM. Predictors of psychosis breakthrough during 24 months of long-acting antipsychotic maintenance treatment in first episode schizophrenia. Schizophr Res 2020;225:55-62. [PMID: 31767510 DOI: 10.1016/j.schres.2019.11.025] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 2.7] [Reference Citation Analysis]
104 Holderness E, Miller N, Cawkwell P, Bolton K, Meteer M, Pustejovsky J, Hall MH. Analysis of risk factor domains in psychosis patient health records. J Biomed Semantics 2019;10:19. [PMID: 31672168 DOI: 10.1186/s13326-019-0210-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
105 Birnbaum ML, Ernala SK, Rizvi AF, Arenare E, R Van Meter A, De Choudhury M, Kane JM. Detecting relapse in youth with psychotic disorders utilizing patient-generated and patient-contributed digital data from Facebook. NPJ Schizophr 2019;5:17. [PMID: 31591400 DOI: 10.1038/s41537-019-0085-9] [Cited by in Crossref: 30] [Cited by in F6Publishing: 33] [Article Influence: 10.0] [Reference Citation Analysis]
106 Stilo SA, Murray RM. Non-Genetic Factors in Schizophrenia. Curr Psychiatry Rep 2019;21:100. [PMID: 31522306 DOI: 10.1007/s11920-019-1091-3] [Cited by in Crossref: 41] [Cited by in F6Publishing: 63] [Article Influence: 13.7] [Reference Citation Analysis]
107 Gómez-Revuelta M, Pelayo-Terán JM, Juncal-Ruiz M, Ortiz-García de la Foz V, Vázquez-Bourgon J, González-Pinto A, Crespo-Facorro B. Long-Term Antipsychotic Effectiveness in First Episode of Psychosis: A 3-Year Follow-Up Randomized Clinical Trial Comparing Aripiprazole, Quetiapine, and Ziprasidone. Int J Neuropsychopharmacol 2018;21:1090-101. [PMID: 30215723 DOI: 10.1093/ijnp/pyy082] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
108 Iwata N, Ishigooka J, Kim WH, Yoon BH, Lin SK, Sulaiman AH, Cosca R, Wang L, Suchkov Y, Agarkov A, Watabe K, Matsui T, Sato T, Inoue Y, Higuchi T, Correll CU, Kane JM. Efficacy and safety of blonanserin transdermal patch in patients with schizophrenia: A 6-week randomized, double-blind, placebo-controlled, multicenter study. Schizophr Res 2020;215:408-15. [PMID: 31471246 DOI: 10.1016/j.schres.2019.07.055] [Cited by in Crossref: 13] [Cited by in F6Publishing: 18] [Article Influence: 4.3] [Reference Citation Analysis]
109 Reid S, Bhattacharyya S. Antipsychotic treatment failure in patients with psychosis and co-morbid cannabis use: A systematic review. Psychiatry Res 2019;280:112523. [PMID: 31450032 DOI: 10.1016/j.psychres.2019.112523] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 2.3] [Reference Citation Analysis]
110 Reynolds S, Kim DJ, Brown E, Tindall R, O’donoghue B. Defining disengagement from mental health services for individuals experiencing first episode psychosis: a systematic review. Soc Psychiatry Psychiatr Epidemiol 2019;54:1325-35. [DOI: 10.1007/s00127-019-01750-6] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
111 Kidd SA, Feldcamp L, Adler A, Kaleis L, Wang W, Vichnevetski K, McKenzie K, Voineskos A. Feasibility and outcomes of a multi-function mobile health approach for the schizophrenia spectrum: App4Independence (A4i). PLoS One 2019;14:e0219491. [PMID: 31306439 DOI: 10.1371/journal.pone.0219491] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 4.3] [Reference Citation Analysis]
112 Bell IH, Alvarez-jimenez M. Digital Technology to Enhance Clinical Care of Early Psychosis. Curr Treat Options Psych 2019;6:256-70. [DOI: 10.1007/s40501-019-00182-y] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.7] [Reference Citation Analysis]
113 Mustafa S, Bougie J, Miguelez M, Clerzius G, Rampakakis E, Proulx J, Malla A. Real-life assessment of aripiprazole monthly (Abilify Maintena) in schizophrenia: a Canadian naturalistic non-interventional prospective cohort study. BMC Psychiatry 2019;19:114. [PMID: 30991969 DOI: 10.1186/s12888-019-2103-x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
114 Olagunju AT, Clark SR, Baune BT. Long-acting atypical antipsychotics in schizophrenia: A systematic review and meta-analyses of effects on functional outcome. Aust N Z J Psychiatry 2019;53:509-27. [PMID: 30957510 DOI: 10.1177/0004867419837358] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 5.0] [Reference Citation Analysis]
115 Weintraub MJ, Weisman de Mamani A, Villano WJ, Evans TC, Millman ZB, Hooley JM, Timpano KR. Affective and physiological reactivity to emotional comments in individuals at elevated risk for psychosis. Schizophrenia Research 2019;206:428-35. [DOI: 10.1016/j.schres.2018.10.006] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
116 Eisner E, Drake RJ, Berry N, Barrowclough C, Emsley R, Machin M, Bucci S. Development and Long-Term Acceptability of ExPRESS, a Mobile Phone App to Monitor Basic Symptoms and Early Signs of Psychosis Relapse. JMIR Mhealth Uhealth 2019;7:e11568. [PMID: 30924789 DOI: 10.2196/11568] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 8.0] [Reference Citation Analysis]
117 Jacques MC, St-Cyr Tribble D, Bonin JP. Filters in the coping process of people with schizophrenia: A constructivist grounded theory study. J Psychiatr Ment Health Nurs 2019;26:142-52. [PMID: 30825402 DOI: 10.1111/jpm.12515] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
118 Alvarez-Jimenez M, Bendall S, Koval P, Rice S, Cagliarini D, Valentine L, D'Alfonso S, Miles C, Russon P, Penn DL, Phillips J, Lederman R, Wadley G, Killackey E, Santesteban-Echarri O, Mihalopoulos C, Herrman H, Gonzalez-Blanch C, Gilbertson T, Lal S, Chambers R, Daglas-Georgiou R, Latorre C, Cotton SM, McGorry PD, Gleeson JF. HORYZONS trial: protocol for a randomised controlled trial of a moderated online social therapy to maintain treatment effects from first-episode psychosis services. BMJ Open 2019;9:e024104. [PMID: 30782893 DOI: 10.1136/bmjopen-2018-024104] [Cited by in Crossref: 37] [Cited by in F6Publishing: 35] [Article Influence: 12.3] [Reference Citation Analysis]
119 Bucci S, Barrowclough C, Ainsworth J, Machin M, Morris R, Berry K, Emsley R, Lewis S, Edge D, Buchan I, Haddock G. Actissist: Proof-of-Concept Trial of a Theory-Driven Digital Intervention for Psychosis. Schizophr Bull 2018;44:1070-80. [PMID: 29566206 DOI: 10.1093/schbul/sby032] [Cited by in Crossref: 87] [Cited by in F6Publishing: 79] [Article Influence: 29.0] [Reference Citation Analysis]
120 McEnery C, Lim MH, Tremain H, Knowles A, Alvarez-Jimenez M. Prevalence rate of social anxiety disorder in individuals with a psychotic disorder: A systematic review and meta-analysis. Schizophr Res 2019;208:25-33. [PMID: 30722947 DOI: 10.1016/j.schres.2019.01.045] [Cited by in Crossref: 10] [Cited by in F6Publishing: 17] [Article Influence: 3.3] [Reference Citation Analysis]
121 Sugawara N, Kudo S, Ishioka M, Sato Y, Kubo K, Yasui-Furukori N. Attitudes toward long-acting injectable antipsychotics among patients with schizophrenia in Japan. Neuropsychiatr Dis Treat 2019;15:205-11. [PMID: 30666117 DOI: 10.2147/NDT.S188337] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
122 Cox DJ, Bolívar HA, Barlow MA. Multiple control responses and resurgence of human behavior. Behav Processes 2019;159:93-9. [PMID: 30529686 DOI: 10.1016/j.beproc.2018.12.003] [Cited by in Crossref: 7] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
123 Suvisaari J, Mantere O, Keinänen J, Mäntylä T, Rikandi E, Lindgren M, Kieseppä T, Raij TT. Is It Possible to Predict the Future in First-Episode Psychosis? Front Psychiatry 2018;9:580. [PMID: 30483163 DOI: 10.3389/fpsyt.2018.00580] [Cited by in Crossref: 28] [Cited by in F6Publishing: 34] [Article Influence: 7.0] [Reference Citation Analysis]
124 Griffiths SL, Wood SJ, Birchwood M. Vulnerability to psychosocial disability in psychosis. Epidemiol Psychiatr Sci 2019;28:140-5. [PMID: 30205855 DOI: 10.1017/S2045796018000495] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
125 Smith LM, Onwumere J, Craig T, Kuipers E. Caregiver correlates of patient-initiated violence in early psychosis. Psychiatry Res 2018;270:412-7. [PMID: 30308465 DOI: 10.1016/j.psychres.2018.09.011] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
126 Puntis S, Oke J, Lennox B. Discharge pathways and relapse following treatment from early intervention in psychosis services. BJPsych Open 2018;4:368-74. [PMID: 30202598 DOI: 10.1192/bjo.2018.50] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
127 Butler R, Berry K, Ellett L, Bucci S. An experimental investigation of the impact of critical and warm comments on state paranoia in a non-clinical sample. J Behav Ther Exp Psychiatry 2019;62:30-7. [PMID: 30179728 DOI: 10.1016/j.jbtep.2018.08.008] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
128 Colizzi M, Burnett N, Costa R, De Agostini M, Griffin J, Bhattacharyya S. Longitudinal assessment of the effect of cannabis use on hospital readmission rates in early psychosis: A 6-year follow-up in an inpatient cohort. Psychiatry Res 2018;268:381-7. [PMID: 30121541 DOI: 10.1016/j.psychres.2018.08.005] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 4.3] [Reference Citation Analysis]
129 Bonet L, Llácer B, Hernandez-Viadel M, Arce D, Blanquer I, Cañete C, Escartí M, González-Pinto AM, Sanjuán J. Differences in the Use and Opinions About New eHealth Technologies Among Patients With Psychosis: Structured Questionnaire. JMIR Ment Health 2018;5:e51. [PMID: 30045835 DOI: 10.2196/mental.9950] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 5.5] [Reference Citation Analysis]
130 DeTore NR, Ventura J, Subotnik KL, Nuechterlein KH. Family burden predicts functional outcome in the early course of schizophrenia beyond psychiatric symptoms and baseline functioning. Schizophr Res 2018;202:328-32. [PMID: 30539770 DOI: 10.1016/j.schres.2018.06.068] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
131 Harvey C, Lewis J, Farhall J. Receipt and targeting of evidence-based psychosocial interventions for people living with psychoses: findings from the second Australian national survey of psychosis. Epidemiol Psychiatr Sci 2019;28:613-29. [PMID: 29893656 DOI: 10.1017/S2045796018000288] [Cited by in Crossref: 1] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
132 Baker AL, Turner A, Beck A, Berry K, Haddock G, Kelly PJ, Bucci S. Telephone-delivered psychosocial interventions targeting key health priorities in adults with a psychotic disorder: systematic review. Psychol Med 2018;48:2637-57. [PMID: 29798730 DOI: 10.1017/S0033291718001125] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
133 Correll CU, Rubio JM, Kane JM. What is the risk-benefit ratio of long-term antipsychotic treatment in people with schizophrenia? World Psychiatry 2018;17:149-60. [PMID: 29856543 DOI: 10.1002/wps.20516] [Cited by in Crossref: 128] [Cited by in F6Publishing: 102] [Article Influence: 32.0] [Reference Citation Analysis]
134 Bustillo M, Zabala A, Querejeta I, Carton JI, Mentxaka O, González-pinto A, García S, Meana JJ, Eguiluz JI, Segarra R. Therapeutic Drug Monitoring of Second-Generation Antipsychotics for the Estimation of Early Drug Effect in First-Episode Psychosis: A Cross-sectional Assessment. Therapeutic Drug Monitoring 2018;40:257-67. [DOI: 10.1097/ftd.0000000000000480] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
135 [DOI: 10.1109/icicct.2018.8472986] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
136 Pelayo-Terán JM, Gajardo-Galán V, Gómez-Revuelta M, Ortiz-García de la Foz V, Ayesa-Arriola R, Tabarés-Seisdedos R, Crespo-Facorro B. Duration of active psychosis and functional outcomes in first-episode non-affective psychosis. Eur Psychiatry 2018;52:29-37. [PMID: 29614389 DOI: 10.1016/j.eurpsy.2018.03.003] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 3.8] [Reference Citation Analysis]
137 Lappin JM, Heslin M, Lomas B, Jones PB, Doody GA, Reininghaus UA, Croudace T, Craig T, Fearon P, Murray RM, Dazzan P, Morgan C. Early sustained recovery following first episode psychosis: Evidence from the AESOP10 follow-up study. Schizophr Res 2018;199:341-5. [PMID: 29571751 DOI: 10.1016/j.schres.2018.03.014] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
138 Guedes de Pinho LM, Pereira AMDS, Chaves CMCB. Quality of life in schizophrenic patients: the influence of sociodemographic and clinical characteristics and satisfaction with social support. Trends Psychiatry Psychother 2018;40:202-9. [DOI: 10.1590/2237-6089-2017-0002] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
139 Lee SU, Soh M, Ryu V, Kim CE, Park S, Roh S, Oh IH, Lee HY, Choi S. Analysis of the Health Insurance Review and Assessment Service data from 2011 to 2015. Int J Ment Health Syst 2018;12:9. [PMID: 29507604 DOI: 10.1186/s13033-018-0187-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
140 Santesteban-echarri O, Paino M, Rice S, González-blanch C, Mcgorry P, Gleeson J, Alvarez-jimenez M. Predictors of functional recovery in first-episode psychosis: A systematic review and meta-analysis of longitudinal studies. Clinical Psychology Review 2017;58:59-75. [DOI: 10.1016/j.cpr.2017.09.007] [Cited by in Crossref: 92] [Cited by in F6Publishing: 110] [Article Influence: 18.4] [Reference Citation Analysis]
141 Malla A, Ota A, Nagamizu K, Perry P, Weiller E, Baker RA. The effect of brexpiprazole in adult outpatients with early-episode schizophrenia: an exploratory study. Int Clin Psychopharmacol 2016;31:307-14. [PMID: 27571460 DOI: 10.1097/YIC.0000000000000140] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
142 Bowtell M, Ratheesh A, McGorry P, Killackey E, O'Donoghue B. Clinical and demographic predictors of continuing remission or relapse following discontinuation of antipsychotic medication after a first episode of psychosis. A systematic review. Schizophr Res 2018;197:9-18. [PMID: 29146020 DOI: 10.1016/j.schres.2017.11.010] [Cited by in Crossref: 26] [Cited by in F6Publishing: 36] [Article Influence: 5.2] [Reference Citation Analysis]
143 Jones N, Godzikovskaya J, Zhao Z, Vasquez A, Gilbert A, Davidson L. Intersecting disadvantage: Unpacking poor outcomes within early intervention in psychosis services. Early Intervention in Psychiatry 2018;13:488-94. [DOI: 10.1111/eip.12508] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
144 Rubio JM, Kane JM. Psychosis breakthrough on antipsychotic maintenance medication (BAMM): what can we learn? NPJ Schizophr 2017;3:36. [PMID: 29021565 DOI: 10.1038/s41537-017-0039-z] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
145 Pilon D, Tandon N, Lafeuille M, Kamstra R, Emond B, Lefebvre P, Joshi K. Treatment Patterns, Health Care Resource Utilization, and Spending in Medicaid Beneficiaries Initiating Second-generation Long-acting Injectable Agents Versus Oral Atypical Antipsychotics. Clinical Therapeutics 2017;39:1972-1985.e2. [DOI: 10.1016/j.clinthera.2017.08.008] [Cited by in Crossref: 36] [Cited by in F6Publishing: 45] [Article Influence: 7.2] [Reference Citation Analysis]
146 Sullivan S, Northstone K, Gadd C, Walker J, Margelyte R, Richards A, Whiting P. Models to predict relapse in psychosis: A systematic review. PLoS One 2017;12:e0183998. [PMID: 28934214 DOI: 10.1371/journal.pone.0183998] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
147 Schoeler T, Petros N, Di Forti M, Klamerus E, Foglia E, Murray R, Bhattacharyya S. Poor medication adherence and risk of relapse associated with continued cannabis use in patients with first-episode psychosis: a prospective analysis. Lancet Psychiatry 2017;4:627-33. [PMID: 28705600 DOI: 10.1016/S2215-0366(17)30233-X] [Cited by in Crossref: 66] [Cited by in F6Publishing: 53] [Article Influence: 13.2] [Reference Citation Analysis]
148 Crosas JM, Cobo J, Ahuir M, Hernández C, García R, Pousa E, Oliva JC, Monreal JA, Palao DJ. Substance abuse and gender differences in first episode psychosis: Impact on hospital readmissions. Rev Psiquiatr Salud Ment (Engl Ed) 2018;11:27-35. [PMID: 28648845 DOI: 10.1016/j.rpsm.2017.04.002] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
149 D'Alfonso S, Santesteban-Echarri O, Rice S, Wadley G, Lederman R, Miles C, Gleeson J, Alvarez-Jimenez M. Artificial Intelligence-Assisted Online Social Therapy for Youth Mental Health. Front Psychol 2017;8:796. [PMID: 28626431 DOI: 10.3389/fpsyg.2017.00796] [Cited by in Crossref: 41] [Cited by in F6Publishing: 40] [Article Influence: 8.2] [Reference Citation Analysis]
150 Bossie CA, Turkoz I, Alphs L, Mahalchick L, Fu DJ. Paliperidone Palmitate Once-Monthly Treatment in Recent Onset and Chronic Illness Patients With Schizoaffective Disorder. J Nerv Ment Dis 2017;205:324-8. [PMID: 28005578 DOI: 10.1097/NMD.0000000000000646] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
151 Lal S, Malla A, Marandola G, Thériault J, Tibbo P, Manchanda R, Williams R, Joober R, Banks N. “Worried about relapse”: Family members’ experiences and perspectives of relapse in first-episode psychosis. Early Intervention in Psychiatry 2019;13:24-9. [DOI: 10.1111/eip.12440] [Cited by in Crossref: 12] [Cited by in F6Publishing: 16] [Article Influence: 2.4] [Reference Citation Analysis]
152 Jansen JE, Lysaker PH, Trauelsen AM, Luther L, Haahr UH, Lyse H, Pedersen MB, Simonsen E. Metacognitive mastery in persons with first-episode psychosis and their caregivers: Implications for timely help-seeking and caregiver experiences. Brief report. Psychiatry Research 2017;251:54-7. [DOI: 10.1016/j.psychres.2017.02.003] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
153 Breitborde NJ, Moe AM, Ered A, Ellman LM, Bell EK. Optimizing psychosocial interventions in first-episode psychosis: current perspectives and future directions. Psychol Res Behav Manag 2017;10:119-28. [PMID: 28490910 DOI: 10.2147/PRBM.S111593] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 3.2] [Reference Citation Analysis]
154 Lenzi J, Iozzino L, De Girolamo G, Rucci P, Tosato S, Lasalvia A, Bonetto C, Ruggeri M. Predictors of 9-month hospitalization in patients with first-episode affective and non-affective psychosis. Results from the GET UP pragmatic cluster randomized controlled trial. Schizophr Res 2017;190:187-8. [PMID: 28347569 DOI: 10.1016/j.schres.2017.03.037] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
155 Sadiq S, Suhail K, Gleeson J, Alvarez-Jimenez M. Expressed emotion and the course of schizophrenia in Pakistan. Soc Psychiatry Psychiatr Epidemiol 2017;52:587-93. [PMID: 28260128 DOI: 10.1007/s00127-017-1357-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
156 Öksüz E, Karaca S, Özaltın G, Ateş MA. The Effects of Psychoeducation on the Expressed Emotion and Family Functioning of the Family Members in First-Episode Schizophrenia. Community Ment Health J 2017;53:464-73. [PMID: 28130726 DOI: 10.1007/s10597-017-0086-y] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
157 Lytle S, McVoy M, Sajatovic M. Long-Acting Injectable Antipsychotics in Children and Adolescents. J Child Adolesc Psychopharmacol 2017;27:2-9. [PMID: 28112539 DOI: 10.1089/cap.2016.0055] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 4.6] [Reference Citation Analysis]
158 Mason L, Peters E, Williams SC, Kumari V. Brain connectivity changes occurring following cognitive behavioural therapy for psychosis predict long-term recovery. Transl Psychiatry 2017;7:e1001. [PMID: 28094811 DOI: 10.1038/tp.2016.263] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 2.6] [Reference Citation Analysis]
159 Gleeson J, Lederman R, Herrman H, Koval P, Eleftheriadis D, Bendall S, Cotton SM, Alvarez-Jimenez M. Moderated online social therapy for carers of young people recovering from first-episode psychosis: study protocol for a randomised controlled trial. Trials 2017;18:27. [PMID: 28095883 DOI: 10.1186/s13063-016-1775-5] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 3.2] [Reference Citation Analysis]
160 Galletly C, Castle D, Dark F, Humberstone V, Jablensky A, Killackey E, Kulkarni J, McGorry P, Nielssen O, Tran N. Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the management of schizophrenia and related disorders. Aust N Z J Psychiatry. 2016;50:410-472. [PMID: 27106681 DOI: 10.1177/0004867416641195] [Cited by in Crossref: 429] [Cited by in F6Publishing: 384] [Article Influence: 85.8] [Reference Citation Analysis]
161 Lo TL, Warden M, He Y, Si T, Kalyanasundaram S, Thirunavukarasu M, Amir N, Hatim A, Bautista T, Lee C, Emsley R, Olivares J, Yang YK, Kongsakon R, Castle D. Recommendations for the optimal care of patients with recent-onset psychosis in the Asia-Pacific region. Asia Pac Psychiatry 2016;8:154-71. [PMID: 27062665 DOI: 10.1111/appy.12234] [Cited by in Crossref: 12] [Cited by in F6Publishing: 16] [Article Influence: 2.4] [Reference Citation Analysis]
162 Crespo-facorro B, Bernardo M, Argimon JM, Arrojo M, Bravo-ortiz MF, Cabrera-cifuentes A, Carretero-román J, Franco-martín MA, García-portilla P, Haro JM, Olivares JM, Penadés R, del Pino-montes J, Sanjuán J, Arango C. Eficacia, eficiencia y efectividad en el tratamiento multidimensional de la esquizofrenia: proyecto Rethinking. Revista de Psiquiatría y Salud Mental 2017;10:4-20. [DOI: 10.1016/j.rpsm.2016.09.001] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
163 Chiang CL, Chen PC, Huang LY, Kuo PH, Tung YC, Liu CC, Chen WJ. Time trends in first admission rates for schizophrenia and other psychotic disorders in Taiwan, 1998-2007: a 10-year population-based cohort study. Soc Psychiatry Psychiatr Epidemiol 2017;52:163-73. [PMID: 28028581 DOI: 10.1007/s00127-016-1326-0] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 2.3] [Reference Citation Analysis]
164 Kishi T, Oya K, Iwata N. Long-acting injectable antipsychotics for the prevention of relapse in patients with recent-onset psychotic disorders: A systematic review and meta-analysis of randomized controlled trials. Psychiatry Res 2016;246:750-5. [PMID: 27863801 DOI: 10.1016/j.psychres.2016.10.053] [Cited by in Crossref: 29] [Cited by in F6Publishing: 24] [Article Influence: 4.8] [Reference Citation Analysis]
165 Pelayo-Terán JM, Gajardo Galán VG, de la Ortiz-García de la Foz V, Martínez-García O, Tabarés-Seisdedos R, Crespo-Facorro B, Ayesa-Arriola R. Rates and predictors of relapse in first-episode non-affective psychosis: a 3-year longitudinal study in a specialized intervention program (PAFIP). Eur Arch Psychiatry Clin Neurosci 2017;267:315-23. [PMID: 27796500 DOI: 10.1007/s00406-016-0740-3] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 4.3] [Reference Citation Analysis]
166 Sands N, Elsom S, Corbett R, Keppich-Arnold S, Prematunga R, Berk M, Considine J. Predictors for clinical deterioration of mental state in patients assessed by telephone-based mental health triage. Int J Ment Health Nurs 2017;26:226-37. [PMID: 27779363 DOI: 10.1111/inm.12267] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
167 Fikreyesus M, Soboka M, Feyissa GT. Psychotic relapse and associated factors among patients attending health services in Southwest Ethiopia: a cross-sectional study. BMC Psychiatry 2016;16:354. [PMID: 27765033 DOI: 10.1186/s12888-016-1076-2] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
168 Schrank B, Rumpold T, Gmeiner A, Priebe S, Aigner M. Parenthood among patients with psychotic disorders: gender differences in a non-selective clinical sample. Psychiatry Res 2016;246:474-9. [PMID: 27792977 DOI: 10.1016/j.psychres.2016.10.020] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
169 Di Capite S, Upthegrove R, Mallikarjun P. The relapse rate and predictors of relapse in patients with first-episode psychosis following discontinuation of antipsychotic medication. Early Interv Psychiatry 2018;12:893-9. [PMID: 27734591 DOI: 10.1111/eip.12385] [Cited by in Crossref: 16] [Cited by in F6Publishing: 20] [Article Influence: 2.7] [Reference Citation Analysis]
170 Schnakenberg Martin AM, Bonfils KA, Davis BJ, Smith EA, Schuder K, Lysaker PH. Compared to high and low cannabis use, moderate use is associated with fewer cognitive deficits in psychosis. Schizophr Res Cogn 2016;6:15-21. [PMID: 28740820 DOI: 10.1016/j.scog.2016.09.001] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 1.7] [Reference Citation Analysis]
171 Dannevang AL, Randers L, Gondan M, Krakauer K, Nordholm D, Nordentoft M. Premorbid adjustment in individuals at ultra-high risk for developing psychosis: a case-control study: Premorbid adjustment in ultra-high risk individuals. Early Intervention in Psychiatry 2018;12:839-47. [DOI: 10.1111/eip.12375] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 1.7] [Reference Citation Analysis]
172 García-Mieres H, Ochoa S, Salla M, López-Carrilero R, Feixas G. Understanding the paranoid psychosis of James: Use of the repertory grid technique for case conceptualization. World J Psychiatr 2016; 6(3): 381-390 [PMID: 27679779 DOI: 10.5498/wjp.v6.i3.381] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
173 Tomita A, Moodley Y. The revolving door of mental, neurological, and substance use disorders re-hospitalization in rural KwaZulu-Natal Province, South Africa. Afr Health Sci 2016;16:817-21. [PMID: 27917216 DOI: 10.4314/ahs.v16i3.23] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
174 Hui CLM, Lo MCL, Chan EHC, Chen ESM, Ko RWT, Lee EHM, Chang WC, Chan SKW, Chen EYH. Perception towards relapse and its predictors in psychosis patients: A qualitative study. Early Interv Psychiatry 2018;12:856-62. [PMID: 27573207 DOI: 10.1111/eip.12378] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
175 Crespo-Facorro B, Pelayo-Teran JM, Mayoral-van Son J. Current Data on and Clinical Insights into the Treatment of First Episode Nonaffective Psychosis: A Comprehensive Review. Neurol Ther 2016;5:105-30. [PMID: 27553839 DOI: 10.1007/s40120-016-0050-8] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 2.7] [Reference Citation Analysis]
176 Schoeler T, Petros N, Di Forti M, Klamerus E, Foglia E, Ajnakina O, Gayer-Anderson C, Colizzi M, Quattrone D, Behlke I, Shetty S, McGuire P, David AS, Murray R, Bhattacharyya S. Effects of continuation, frequency, and type of cannabis use on relapse in the first 2 years after onset of psychosis: an observational study. Lancet Psychiatry 2016;3:947-53. [PMID: 27567467 DOI: 10.1016/S2215-0366(16)30188-2] [Cited by in Crossref: 89] [Cited by in F6Publishing: 78] [Article Influence: 14.8] [Reference Citation Analysis]
177 Hui CL, Chiu CP, Li YK, Law CW, Chang WC, Chan SK, Lee EH, Sham P, Chen EY. The Effect of Paternal Age on Relapse in First-Episode Schizophrenia. Can J Psychiatry 2015;60:346-53. [PMID: 26454556 DOI: 10.1177/070674371506000803] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
178 Williams R, Malla A, Roy MA, Joober R, Manchanda R, Tibbo P, Banks N, Agid O. What Is the Place of Clozapine in the Treatment of Early Psychosis in Canada? Can J Psychiatry 2017;62:109-14. [PMID: 27310245 DOI: 10.1177/0706743716651049] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
179 De Hert M, Sermon J, Geerts P, Vansteelandt K, Peuskens J, Detraux J. The Use of Continuous Treatment Versus Placebo or Intermittent Treatment Strategies in Stabilized Patients with Schizophrenia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials with First- and Second-Generation Antipsychotics. CNS Drugs 2015;29:637-58. [PMID: 26293744 DOI: 10.1007/s40263-015-0269-4] [Cited by in Crossref: 44] [Cited by in F6Publishing: 48] [Article Influence: 7.3] [Reference Citation Analysis]
180 Bentley E, Millman ZB, Thompson E, Demro C, Kline E, Pitts SC, Devylder JE, Smith ME, Reeves G, Schiffman J. High-risk diagnosis, social stress, and parent-child relationships: A moderation model. Schizophrenia Research 2016;174:65-70. [DOI: 10.1016/j.schres.2016.04.014] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 1.8] [Reference Citation Analysis]
181 Dewa CS, Trojanowski L, Cheng C, Hoch JS. Potential Effects of the Choice of Costing Perspective on Cost Estimates: An Example Based on 6 Early Psychosis Intervention Programs. Can J Psychiatry 2016;61:471-9. [PMID: 27310225 DOI: 10.1177/0706743716639917] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
182 Hui CLM, Li YK, Li AWY, Lee EHM, Chang WC, Chan SKW, Lam SY, Thornton AE, Sham P, Honer WG, Chen EYH. Visual working memory deterioration preceding relapse in psychosis. Psychol Med 2016;46:2435-44. [DOI: 10.1017/s0033291716000751] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
183 Veling W, Pot-Kolder R, Counotte J, van Os J, van der Gaag M. Environmental Social Stress, Paranoia and Psychosis Liability: A Virtual Reality Study. Schizophr Bull 2016;42:1363-71. [PMID: 27038469 DOI: 10.1093/schbul/sbw031] [Cited by in Crossref: 62] [Cited by in F6Publishing: 66] [Article Influence: 10.3] [Reference Citation Analysis]
184 Lawrie SM, O’donovan MC, Saks E, Burns T, Lieberman JA. Towards diagnostic markers for the psychoses. The Lancet Psychiatry 2016;3:375-85. [DOI: 10.1016/s2215-0366(16)00021-3] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 2.7] [Reference Citation Analysis]
185 Chiang CL, Chen PC, Huang LY, Kuo PH, Tung YC, Liu CC, Chen WJ. Impact of universal health coverage on urban-rural inequity in psychiatric service utilisation for patients with first admission for psychosis: a 10-year nationwide population-based study in Taiwan. BMJ Open 2016;6:e010802. [PMID: 26940114 DOI: 10.1136/bmjopen-2015-010802] [Cited by in Crossref: 14] [Cited by in F6Publishing: 18] [Article Influence: 2.3] [Reference Citation Analysis]
186 Davies G, Haddock G, Yung AR, Mulligan LD, Kyle SD. A systematic review of the nature and correlates of sleep disturbance in early psychosis. Sleep Med Rev 2017;31:25-38. [PMID: 26920092 DOI: 10.1016/j.smrv.2016.01.001] [Cited by in Crossref: 56] [Cited by in F6Publishing: 70] [Article Influence: 9.3] [Reference Citation Analysis]
187 Allard J, Lancaster S, Clayton S, Amos T, Birchwood M. Carers' and service users' experiences of early intervention in psychosis services: implications for care partnerships. Early Interv Psychiatry 2018;12:410-6. [PMID: 26758476 DOI: 10.1111/eip.12309] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 1.7] [Reference Citation Analysis]
188 Chi MH, Hsiao CY, Chen KC, Lee L, Tsai HC, Hui Lee I, Chen PS, Yang YK. The readmission rate and medical cost of patients with schizophrenia after first hospitalization — A 10-year follow-up population-based study. Schizophrenia Research 2016;170:184-90. [DOI: 10.1016/j.schres.2015.11.025] [Cited by in Crossref: 19] [Cited by in F6Publishing: 22] [Article Influence: 3.2] [Reference Citation Analysis]
189 Beck AK, Baker A, Turner A, Haddock G, Kelly PJ, Berry K, Bucci S. Protocol for a systematic review of telephone delivered psychosocial interventions on relapse prevention, adherence to psychiatric medication and health risk behaviours in adults with a psychotic disorder. BMJ Open 2015;5:e009985. [PMID: 26700289 DOI: 10.1136/bmjopen-2015-009985] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
190 Colizzi M, Carra E, Fraietta S, Lally J, Quattrone D, Bonaccorso S, Mondelli V, Ajnakina O, Dazzan P, Trotta A, Sideli L, Kolliakou A, Gaughran F, Khondoker M, David AS, Murray RM, MacCabe JH, Di Forti M. Substance use, medication adherence and outcome one year following a first episode of psychosis. Schizophr Res 2016;170:311-7. [PMID: 26718334 DOI: 10.1016/j.schres.2015.11.016] [Cited by in Crossref: 45] [Cited by in F6Publishing: 40] [Article Influence: 6.4] [Reference Citation Analysis]
191 Loft NO, Lavender T. Exploring compulsory admission experiences of adults with psychosis in the UK using Grounded Theory. J Ment Health 2016;25:297-302. [PMID: 26607477 DOI: 10.3109/09638237.2015.1101415] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
192 Quah SR. Partnership: The Missing Link in the Process of De-Institutionalization of Mental Health Care. Int J Health Serv 2017;47:532-49. [DOI: 10.1177/0020731415614512] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
193 Henderson C, Knapp M, Yeeles K, Bremner S, Eldridge S, David AS, O'Connell N, Burns T, Priebe S. Cost-Effectiveness of Financial Incentives to Promote Adherence to Depot Antipsychotic Medication: Economic Evaluation of a Cluster-Randomised Controlled Trial. PLoS One 2015;10:e0138816. [PMID: 26448540 DOI: 10.1371/journal.pone.0138816] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
194 Håkansson A, Johansson BA. Atypical course in severe catatonic schizophrenia in a cannabis-dependent male adolescent: a case report. J Med Case Rep 2015;9:200. [PMID: 26388066 DOI: 10.1186/s13256-015-0678-5] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
195 Bucci S, Barrowclough C, Ainsworth J, Morris R, Berry K, Machin M, Emsley R, Lewis S, Edge D, Buchan I, Haddock G. Using mobile technology to deliver a cognitive behaviour therapy-informed intervention in early psychosis (Actissist): study protocol for a randomised controlled trial. Trials 2015;16:404. [PMID: 26357943 DOI: 10.1186/s13063-015-0943-3] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 3.6] [Reference Citation Analysis]
196 Haney M, Evins AE. Does Cannabis Cause, Exacerbate or Ameliorate Psychiatric Disorders? An Oversimplified Debate Discussed. Neuropsychopharmacology 2016;41:393-401. [PMID: 26286840 DOI: 10.1038/npp.2015.251] [Cited by in Crossref: 44] [Cited by in F6Publishing: 40] [Article Influence: 6.3] [Reference Citation Analysis]
197 Koutra K, Triliva S, Roumeliotaki T, Basta M, Lionis C, Vgontzas AN. Family Functioning in First-Episode and Chronic Psychosis: The Role of Patient's Symptom Severity and Psychosocial Functioning. Community Ment Health J 2016;52:710-23. [PMID: 26286079 DOI: 10.1007/s10597-015-9916-y] [Cited by in Crossref: 16] [Cited by in F6Publishing: 21] [Article Influence: 2.3] [Reference Citation Analysis]
198 Yeo S, Park J, Jang J, Kang N, Cui Y, Kim M, Kim H, Jung A, Chung Y. Acceptance rate of long-acting injection after short information: a survey in patients with first- and multiple-episode psychoses and their caregivers: LAI acceptance in FEP, MEP, caregivers. Early Intervention in Psychiatry 2017;11:509-16. [DOI: 10.1111/eip.12262] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
199 Xiao J, Mi W, Li L, Shi Y, Zhang H. High relapse rate and poor medication adherence in the Chinese population with schizophrenia: results from an observational survey in the People's Republic of China. Neuropsychiatr Dis Treat 2015;11:1161-7. [PMID: 26056450 DOI: 10.2147/NDT.S72367] [Cited by in Crossref: 15] [Cited by in F6Publishing: 21] [Article Influence: 2.1] [Reference Citation Analysis]
200 Pawełczyk T, Grancow M, Kotlicka-Antczak M, Trafalska E, Gębski P, Szemraj J, Żurner N, Pawełczyk A. Omega-3 fatty acids in first-episode schizophrenia - a randomized controlled study of efficacy and relapse prevention (OFFER): rationale, design, and methods. BMC Psychiatry 2015;15:97. [PMID: 25934131 DOI: 10.1186/s12888-015-0473-2] [Cited by in Crossref: 27] [Cited by in F6Publishing: 28] [Article Influence: 3.9] [Reference Citation Analysis]
201 Leclerc E, Noto C, Bressan RA, Brietzke E. Determinants of adherence to treatment in first-episode psychosis: a comprehensive review. Rev Bras Psiquiatr 2015;37:168-76. [DOI: 10.1590/1516-4446-2014-1539] [Cited by in Crossref: 29] [Cited by in F6Publishing: 34] [Article Influence: 4.1] [Reference Citation Analysis]
202 Dixon LB, Goldman HH, Bennett ME, Wang Y, McNamara KA, Mendon SJ, Goldstein AB, Choi CW, Lee RJ, Lieberman JA, Essock SM. Implementing Coordinated Specialty Care for Early Psychosis: The RAISE Connection Program. Psychiatr Serv 2015;66:691-8. [PMID: 25772764 DOI: 10.1176/appi.ps.201400281] [Cited by in Crossref: 80] [Cited by in F6Publishing: 80] [Article Influence: 11.4] [Reference Citation Analysis]
203 San L, Serrano M, Cañas F, Romero SL, Sánchez-cabezudo Á, Villar M. Towards a pragmatic and operational definition of relapse in schizophrenia: A Delphi consensus approach. International Journal of Psychiatry in Clinical Practice 2015;19:90-8. [DOI: 10.3109/13651501.2014.1002501] [Cited by in Crossref: 8] [Cited by in F6Publishing: 12] [Article Influence: 1.1] [Reference Citation Analysis]
204 Tibbo P, Malla A, Manchanda R, Williams R, Joober R. Relapse risk assessment in early phase psychosis: the search for a reliable and valid tool. Can J Psychiatry 2014;59:655-8. [PMID: 25702366 DOI: 10.1177/070674371405901207] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.7] [Reference Citation Analysis]
205 Drake RJ, Nordentoft M, Haddock G, Arango C, Fleischhacker WW, Glenthøj B, Leboyer M, Leucht S, Leweke M, McGuire P, Meyer-Lindenberg A, Rujescu D, Sommer IE, Kahn RS, Lewis SW. Modeling determinants of medication attitudes and poor adherence in early nonaffective psychosis: implications for intervention. Schizophr Bull 2015;41:584-96. [PMID: 25750247 DOI: 10.1093/schbul/sbv015] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 3.9] [Reference Citation Analysis]
206 Del Rey-mejías Á, Fraguas D, Díaz-caneja CM, Pina-camacho L, Castro-fornieles J, Baeza I, Espliego A, Merchán-naranjo J, González-pinto A, de la Serna E, Payá B, Graell M, Arango C, Parellada M. Functional deterioration from the premorbid period to 2 years after the first episode of psychosis in early-onset psychosis. Eur Child Adolesc Psychiatry 2015;24:1447-59. [DOI: 10.1007/s00787-015-0693-5] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
207 Heres S, Lambert M, Vauth R. Treatment of early episode in patients with schizophrenia: the role of long acting antipsychotics. Eur Psychiatry 2014;29 Suppl 2:1409-13. [PMID: 25455704 DOI: 10.1016/S0924-9338(14)70001-X] [Cited by in Crossref: 57] [Cited by in F6Publishing: 54] [Article Influence: 7.1] [Reference Citation Analysis]
208 Liemburg EJ, Castelein S, van Es F, Scholte-Stalenhoef AN, van de Willige G, Smid H, Visser E, Knegtering H, Bruggeman R. The Psychosis Recent Onset GRoningen Survey (PROGR-S): defining dimensions and improving outcomes in early psychosis. PLoS One 2014;9:e113521. [PMID: 25412332 DOI: 10.1371/journal.pone.0113521] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
209 Barbeito S, Vega P, Ruiz de Azua S, Balanza-Martinez V, Colom F, Lorente E, Luengo A, Cerrillo E, Crespo JM, González Pinto A. Integrated treatment of first episode psychosis with online training (e-learning): study protocol for a randomised controlled trial. Trials 2014;15:416. [PMID: 25348346 DOI: 10.1186/1745-6215-15-416] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
210 Samalin L, Abbar M, Courtet P, Guillaume S, Lancrenon S, Llorca PM. [French Society for Biological Psychiatry and Neuropsychopharmacology task force: Formal Consensus for the prescription of depot antipsychotics]. Encephale 2013;39 Suppl 4:189-203. [PMID: 24373464 DOI: 10.1016/S0013-7006(13)70121-0] [Cited by in Crossref: 22] [Cited by in F6Publishing: 17] [Article Influence: 2.8] [Reference Citation Analysis]
211 González-Blanch C, Gleeson JF, Cotton SM, Crisp K, McGorry PD, Alvarez-Jimenez M. Longitudinal relationship between expressed emotion and cannabis misuse in young people with first-episode psychosis. Eur Psychiatry 2015;30:20-5. [PMID: 25174270 DOI: 10.1016/j.eurpsy.2014.07.002] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
212 Subotnik KL, Ventura J, Gretchen-Doorly D, Hellemann GS, Agee ER, Casaus LR, Luo JS, Villa KF, Nuechterlein KH. The impact of second-generation antipsychotic adherence on positive and negative symptoms in recent-onset schizophrenia. Schizophr Res 2014;159:95-100. [PMID: 25108771 DOI: 10.1016/j.schres.2014.07.008] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
213 Chan KWS, Wong MHM, Hui CLM, Lee EHM, Chang WC, Chen EYH. Perceived risk of relapse and role of medication: comparison between patients with psychosis and their caregivers. Soc Psychiatry Psychiatr Epidemiol 2015;50:307-15. [DOI: 10.1007/s00127-014-0930-0] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
214 Suzuki T, Uchida H, Takeuchi H, Tsuboi T, Hirano J, Mimura M. A review on schizophrenia and relapse-a quest for user-friendly psychopharmacotherapy: SCHIZOPHRENIA AND RELAPSE. Hum Psychopharmacol Clin Exp 2014;29:414-26. [DOI: 10.1002/hup.2421] [Cited by in Crossref: 18] [Cited by in F6Publishing: 25] [Article Influence: 2.3] [Reference Citation Analysis]
215 Eisner E, Barrowclough C, Lobban F, Drake R. Qualitative investigation of targets for and barriers to interventions to prevent psychosis relapse. BMC Psychiatry 2014;14:201. [PMID: 25030092 DOI: 10.1186/1471-244X-14-201] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
216 Patel M, Chawla R, Krynicki CR, Rankin P, Upthegrove R. Health beliefs and carer burden in first episode psychosis. BMC Psychiatry 2014;14:171. [PMID: 24913656 DOI: 10.1186/1471-244X-14-171] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 2.3] [Reference Citation Analysis]
217 Jansen JE, Harder S, Haahr UH, Lyse HG, Pedersen MB, Trauelsen AM, Simonsen E. The Role of Metacognitions in Expressed Emotion and Distress: A Study on Caregivers of Persons with First-Episode Psychosis. Clin Psychol Psychother 2015;22:525-32. [PMID: 24889322 DOI: 10.1002/cpp.1907] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
218 Casacchia M, Roncone R. Italian Families and Family Interventions. Journal of Nervous & Mental Disease 2014;202:487-97. [DOI: 10.1097/nmd.0000000000000149] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
219 Nilsen L, Frich JC, Friis S, Norheim I, Røssberg JI. Participants' perceived benefits of family intervention following a first episode of psychosis: a qualitative study. Early Interv Psychiatry 2016;10:152-9. [PMID: 24861325 DOI: 10.1111/eip.12153] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 2.3] [Reference Citation Analysis]
220 Alvarez-Jimenez M, Alcazar-Corcoles MA, González-Blanch C, Bendall S, McGorry PD, Gleeson JF. Online, social media and mobile technologies for psychosis treatment: a systematic review on novel user-led interventions. Schizophr Res 2014;156:96-106. [PMID: 24746468 DOI: 10.1016/j.schres.2014.03.021] [Cited by in Crossref: 212] [Cited by in F6Publishing: 187] [Article Influence: 26.5] [Reference Citation Analysis]
221 Matheson SL, Shepherd AM, Carr VJ. How much do we know about schizophrenia and how well do we know it? Evidence from the Schizophrenia Library. Psychol Med 2014;44:3387-405. [PMID: 25065407 DOI: 10.1017/S0033291714000166] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
222 Howes OD, Murray RM. Schizophrenia: an integrated sociodevelopmental-cognitive model. Lancet. 2014;383:1677-1687. [PMID: 24315522 DOI: 10.1016/s0140-6736(13)62036-x] [Cited by in Crossref: 404] [Cited by in F6Publishing: 431] [Article Influence: 44.9] [Reference Citation Analysis]
223 Kam SM, Singh SP, Upthegrove R. What needs to follow early intervention? Predictors of relapse and functional recovery following first-episode psychosis. Early Interv Psychiatry 2015;9:279-83. [PMID: 24251970 DOI: 10.1111/eip.12099] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 2.9] [Reference Citation Analysis]
224 Hui CL, Wong GH, Tang JY, Chang W, Chan SK, Lee EH, Lam MM, Chiu CP, Law C, Chung DW, Tso S, Pang EP, Chan K, Wong Y, Mo FY, Chan KP, Hung S, Honer WG, Chen EY. Predicting 1-year risk for relapse in patients who have discontinued or continued quetiapine after remission from first-episode psychosis. Schizophrenia Research 2013;150:297-302. [DOI: 10.1016/j.schres.2013.08.010] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 2.2] [Reference Citation Analysis]
225 Lee G, Barrowclough C, Lobban F. Positive affect in the family environment protects against relapse in first-episode psychosis. Soc Psychiatry Psychiatr Epidemiol 2014;49:367-76. [PMID: 24081324 DOI: 10.1007/s00127-013-0768-x] [Cited by in Crossref: 42] [Cited by in F6Publishing: 40] [Article Influence: 4.7] [Reference Citation Analysis]
226 Barder HE, Sundet K, Rund BR, Evensen J, Haahr U, ten Velden Hegelstad W, Joa I, Johannessen JO, Langeveld H, Larsen T, Melle I, Opjordsmoen S, Røssberg JI, Simonsen E, Vaglum P, Mcglashan T, Friis S. Neurocognitive development in first episode psychosis 5years follow-up: Associations between illness severity and cognitive course. Schizophrenia Research 2013;149:63-9. [DOI: 10.1016/j.schres.2013.06.016] [Cited by in Crossref: 33] [Cited by in F6Publishing: 34] [Article Influence: 3.7] [Reference Citation Analysis]
227 Gaebel W, Riesbeck M. Are there clinically useful predictors and early warning signs for pending relapse? Schizophr Res 2014;152:469-77. [PMID: 23978776 DOI: 10.1016/j.schres.2013.08.003] [Cited by in Crossref: 16] [Cited by in F6Publishing: 19] [Article Influence: 1.8] [Reference Citation Analysis]
228 Emsley R, Chiliza B, Asmal L. The evidence for illness progression after relapse in schizophrenia. Schizophrenia Research 2013;148:117-21. [DOI: 10.1016/j.schres.2013.05.016] [Cited by in Crossref: 68] [Cited by in F6Publishing: 71] [Article Influence: 7.6] [Reference Citation Analysis]
229 Hui CL, Lee EH, Chang W, Chan SK, Li Y, Lee JT, Chen EY. Sexual dysfunction in Chinese patients with first-episode psychosis: prevalence, clinical correlates and functioning. Schizophrenia Research 2013;148:181-2. [DOI: 10.1016/j.schres.2013.06.004] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
230 Hui CL, Tang JY, Leung CM, Wong GH, Chang WC, Chan SK, Lee EH, Chen EY. A 3-year retrospective cohort study of predictors of relapse in first-episode psychosis in Hong Kong. Aust N Z J Psychiatry 2013;47:746-53. [PMID: 23612934 DOI: 10.1177/0004867413487229] [Cited by in Crossref: 28] [Cited by in F6Publishing: 29] [Article Influence: 3.1] [Reference Citation Analysis]
231 Batalla A, Garcia-Rizo C, Castellví P, Fernandez-Egea E, Yücel M, Parellada E, Kirkpatrick B, Martin-Santos R, Bernardo M. Screening for substance use disorders in first-episode psychosis: implications for readmission. Schizophr Res 2013;146:125-31. [PMID: 23517662 DOI: 10.1016/j.schres.2013.02.031] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 1.6] [Reference Citation Analysis]
232 Emsley R, Chiliza B, Asmal L, Harvey BH. The nature of relapse in schizophrenia. BMC Psychiatry 2013;13:50. [PMID: 23394123 DOI: 10.1186/1471-244X-13-50] [Cited by in Crossref: 186] [Cited by in F6Publishing: 213] [Article Influence: 20.7] [Reference Citation Analysis]
233 Alvarez-jimenez M, Bendall S, Lederman R, Wadley G, Chinnery G, Vargas S, Larkin M, Killackey E, Mcgorry P, Gleeson J. On the HORYZON: Moderated online social therapy for long-term recovery in first episode psychosis. Schizophrenia Research 2013;143:143-9. [DOI: 10.1016/j.schres.2012.10.009] [Cited by in Crossref: 147] [Cited by in F6Publishing: 127] [Article Influence: 16.3] [Reference Citation Analysis]
234 Alvarez-jimenez M, Gleeson JF. Connecting the dots: Twenty-first century technologies to tackle twenty-first century challenges in early intervention. Aust N Z J Psychiatry 2012;46:1194-6. [DOI: 10.1177/0004867412464067] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]